Pulmonary vein isolation is the cornerstone of ablation for persistent atrial fibrillation (AF). The role of balloon catheters in this patient population remains ill defined. We sought to compare efficacy and safety of the laser balloon (LB) with wide-area circumferential pulmonary vein isolation using irrigated radiofrequency current (RF) ablation and 3-dimensional mapping.
T
here is unequivocal consensus that catheter ablation in patients with symptomatic paroxysmal atrial fibrillation (AF) should aim for electric pulmonary vein isolation (PVI). 1 In more advanced disease stages, such as persistent AF, uncertainty exists on the ideal ablation strategy, but experts agree that electric PVI is the minimal interventional end point.
Recent study results endorse the strategy of electric PVI for patients with persistent AF and called into question the incremental value of additional left atrial (LA) substrate modification by linear ablation or by eliminating complex fractionated atrial electrograms. 2, 3 Balloon catheters, such as the cryoballoon (ArcticFront Advance; Medtronic) and the laser balloon (LB; HeartLight; CardioFocus, Marlborough, MA), have proven ample efficacy in achieving durable PVI. [4] [5] [6] [7] Nonrandomized observational studies report clinical success rates comparable with wide-area circumferential PVI using irrigated radiofrequency current (RF) ablation in conjunction with a 3-dimensional mapping system. 8, 9 WHAT IS KNOWN?
• Circumferential pulmonary vein isolation using irrigated radiofrequency current ablation is the mainstay of therapy in patients with persistent atrial fibrillation.
• Balloon catheters are similarly effective in establishing stable sinus rhythm as point-by-point radiofrequency current ablation in patients with paroxysmal atrial fibrillation.
WHAT THE STUDY ADDS?
• In this prospectively randomized multicenter study, for the first time, laser balloon ablation demonstrated to be similarly effective as wide-area circumferential radiofrequency current ablation in patients with persistent atrial fibrillation. • Small enrolling centers achieved similar success rates as large enrolling centers suggesting only for laser balloon ablation suggesting a steep learning curve.
Despite the aforementioned studies, the role of balloon catheters in the treatment of patients with persistent AF remains ill defined.
Therefore, we sought to compare efficacy and safety of visually guided PVI using the LB with the gold standard of wide-area circumferential PVI using irrigated RF ablation and 3-dimensional mapping in a prospective randomized multicenter study.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure because at the time of study start, this permission was not implemented in the patient-informed consent. The study was approved by all local ethic committees and was registered at www.clinicaltrials.org (NCT01863472). The study complies with the Declaration of Helsinki. Patients had to sign the patient-informed consent form before enrollment.
Patient Population
Patients with symptomatic persistent AF refractory to the treatment of at least 1 antiarrhythmic drug (AAD), including β-blockers (class I-III), with an episode duration of >7 days and <1 year were eligible to enter the study. Patients had to be 18 to 80 years old. Mild-to-moderate LA enlargement ≤50 mm was allowed, as well as a mildly reduced left ventricular ejection fraction (>45%).
Patients were excluded if they had had previous PVI attempts or were ineligible for treatment with oral anticoagulation. Moreover, presence of an intracardiac thrombus and moderate or severe mitral valve disease led to exclusion from the study. Preprocedural imaging to assess pulmonary vein (PV) anatomy was not required.
Study End Points
The efficacy end point was defined as freedom from AF or any atrial tachyarrhythmia lasting >30 seconds between days 90 and 365 after the index procedure.
The safety end point was defined as the incidence of periprocedural complications, such as major bleeding requiring intervention, phrenic nerve palsy, pericardial tamponade, thromboembolic events, atrio-to-esophageal fistula, or death.
Preablation Protocol
To exclude intracardiac thrombi and to assess potential mitral valve disease preprocedural transesophageal echocardiography was mandatory. Baseline ECG was acquired, and blood testing was performed to exclude secondary causes for AF.
Anticoagulation was continued or halted as per center's standard.
Randomization
After informed written consent was obtained, patients were randomized in blocks per site in a 1:1 fashion by a clinical research organization (I med pro; Cologne, Germany) using a computerized randomization process. In total, 6 blocks of 48 patients were used for randomization.
Catheter Ablation
Ablation procedures were performed under deep sedation with boluses of midazolam and fentanyl followed by a continuous infusion of propofol. A temperature probe (SensiTherm; St. Jude Medical, St. Paul, MN) was inserted in the esophagus to avoid thermal injury (temperature cutoff limit of 39°C).
After positioning of a decapolar catheter in the coronary sinus, transseptal puncture was performed using the modified Brockenbrough technique. An 8.5F sheath (SL1; St. Jude Medical, Minneapolis, MN) was advanced into the LA. In case of RF ablation, a second transseptal sheath was inserted for the circular mapping catheter (LASSO; Biosense Webster, Diamond Bar, CA).
Unfractionated heparin was repeatedly administered to maintain an activated clotting time between 300 and 400 seconds throughout the procedure. The transseptal sheaths were flushed with heparinized saline at 10 mL/h using a syringe pump (RF) or with a pressure bag (LB) ensuring continuous flushing.
Selective PV angiographies in a right anterior oblique 30° and left anterior oblique 40° projection were performed to assess PV anatomy and to position a circular mapping catheter at the PV ostium to record baseline PV potentials.
LB Ablation
The transseptal sheath was exchanged for a 12F steerable sheath (CardioFocus) via a guidewire in the left superior PV. The LB was navigated to each individual PV using the steerable sheath and inflated to obtain optimal PV occlusion. Laser energy was deployed in a point-by-point fashion thereby covering 30° of a circle with each ablation lesion. The energy level was titrated according to the degree of tissue exposure between 5.5 and 12 W. Energy was applied for 20 to 30 seconds, respectively.
During ablation at the right PVs, diaphragmatic function was monitored by continuous pacing of the right phrenic nerve with a 6F diagnostic catheter positioned in the superior vena cava.
After complete visually guided circular ablation, the PVs were remapped using the circular mapping catheter. In case of residual LA-to-PV conduction, additional ablation was performed using the LB according to the activation sequence in the circular mapping catheter as recently described. 10 Electric PVI was defined as entrance block.
RF Ablation
A mapping catheter (NaviStar Thermocool or SmartTouch Thermocool; Biosense Webster, Diamond Bar, CA) was introduced into the LA to acquire a 3-dimensional electroanatomical map. After defining the LA-to-PV junction using fluoroscopic and electric information, a wide-area circumferential ablation around the ipsilateral PVs was performed. Electric PVI was assessed online by the circular mapping catheter located in one of the ipsilateral PVs. Then, the circular mapping catheter was moved to the other ipsilateral PV to ensure PVI. Ablation was performed with a power of 25 to 40 W, flush rate of 8 to 30 mL/min, and a maximum temperature of 43°C. In case contact force catheters were used, operators aimed at force values between 5 and 40 g, but the protocol did not specify the individual parameters.
In both groups, restoration of sinus rhythm was attempted by direct current cardioversion (≤3×) to reassess complete electric PVI as defined as entrance block. Further, PVI was documented 30 minutes after the last ablation. In case of LA-to-PV reconduction, further ablation was performed until PVI.
If cardioversion failed to restore sinus rhythm, despite PVI, it was left to the discretion of the operator to add further ablation lesions (substrate modification) or apply AADs.
Postprocedural Care
All patients underwent postinterventional transthoracic echocardiography to exclude pericardial effusion. Therapeutic anticoagulation was continued or resumed the day after the procedure. Before discharge, an ECG was obtained to exclude arrhythmia recurrence.
It was encouraged to stop all previously ineffective AADs immediately after the procedure. At day 90 after ablation (blanking period), all AADs had to be stopped.
Follow-Up
A blanking period of 90 days was applied. All patients attended outpatient clinic visits, including 72-hour Holter ECG at 3, 6, and 12 months. In case of symptoms suggestive of an arrhythmia recurrence, 24-hour Holter ECGs were performed or patients received an external event monitor. A recurrence was defined as any documented atrial tachyarrhythmia episode lasting >30 seconds.
All follow-up visits were documented in a case report form that was collected, monitored, and transferred to a digital database by an external clinical research organization (imedpro, Cologne, Germany).
Statistical Analysis
An external and independent biostatistician (ClinStat GmbH, Cologne, Germany) performed the statistical analysis. Mean±SD was used to describe continuous variables with normal distribution. Median and interquartile range were used when appropriate. The Student t test was performed to calculate differences between groups of variable with normal distribution. The χ 2 test or the Fisher exact test were used to perform between group comparisons. The confidence interval (CI) and test statistic were constructed for this study according to the adjusted Wald method. For Patients with persistent atrial fibrillation (AF) were randomized to undergo pulmonary vein isolation (PVI) using a laser balloon (LB) or wide-area circumferential ablation using irrigated radiofrequency current (RF). The primary end point was freedom from AF between 90 and 365 d after a single ablation.
time-to-event data, Kaplan-Meier curves and log-rank test were computed using custom software (SAS 9.4; SAS Institute, Cary, NC).
RESULTS
In this study, 152 patients were enrolled, and 145 underwent catheter ablation. The details for withholding ablation are given in Figure 1 . At the end of the 12 months of follow-up, 134 patients had completed all follow-up visits and thus were evaluated as the perprotocol population for the efficacy end point. In addition, the results of the intention-to-treat population for the efficacy end point will be reported.
Patient Characteristics
No significant differences between the groups with respect to age, sex, LA size, and left ventricular ejection fraction were noted (Table 1) .
Patients had a mean total AF history of 26 (LB) to 35 (RF) months (P=0. 22) , and the vast majority of patients had already undergone cardioversion. In both groups, 40% of patients had been treated with membraneactive AADs (class I or III).
Procedural Data
At the beginning of the procedure, 20 (29%) and 26 (39%) patients presented in normal sinus rhythm in the LB and RF groups, respectively (P=0.27). In all patients, the end point of electric PVI was achieved. In the RF group, 22 (33%), 19 (29%), 15 (23%), and 10 (15%) patients of the per-protocol population were treated with a conventional irrigated tip, surround-flow irrigated tip, contact force, and surround-flow contact force catheter, respectively.
Procedure and fluoroscopy times were similar in both groups (Table 2) , although more time was spent on ablation (eg, time between the first and the last energy application) in the LB group (73±32 versus 62±41 minutes; P=0.068). The average energy Class III (%) 17 (25) 17 (26) Values are mean (±SD), n (%). AF indicates atrial fibrillation; BMI, body mass index; CV, cardioversion; LB, laser balloon; and RF, radiofrequency current. No Values are mean (±SD), n (%). CFAE indicates complex fractionated atrial electrograms; LAI, left atrial isthmus; LB, laser balloon; LIPV, left inferior pulmonary vein; LPV, left pulmonary vein; LSPV, left superior pulmonary vein; NC, not calculated; RAI, right atrial isthmus; RF, radiofrequency current; RIPV, right inferior pulmonary vein; RPV, right pulmonary vein; and RSPV, right superior pulmonary vein.
*Time between the first and the last energy application.
deployed per PV was 6111±3501 and 9879±7358 Ws in the LB and RF groups, respectively. Esophageal temperature rises were observed in 51% (LB) and 53% (RF) of patients. During the procedure, electric cardioversion was performed in 44 and 38 patients in the LB and RF groups, respectively (P=0.48).
The percentage of PVs that reconnected by the end of the 30-minute waiting period was 2.6% (7 of 272) for LB and 4.9% (13 of 264) for RF (P=0.17).
Additional ablation before cardioversion was performed in 1 and 5 patients in the LB (right atrial [RA] isthmus line for typical RA flutter) and RF groups, respectively (n=3, RA isthmus line; n=1, LA isthmus line). In the RF group, 1 patient underwent LA complex fractionated atrial electrogram ablation because of failed cardioversion and was successfully cardioverted thereafter.
Clinical Outcome
Adherence to the follow-up protocol was 92.4%, for example, 134 of 145 patients completed all scheduled visits, including Holter monitoring.
For the per-protocol population, the efficacy end point was met by 71.2% (CI, 60.0%-82.4%) versus 69.3% (CI, 57.5%-81.2%), in the LB and RF groups at 12 months, respectively (P=0.40 for superiority). The Kaplan-Meier survival curves are shown in Figure 2 . Of 26 arrhythmia events in the 19 LB patients with atrial tachycardia (AT)/AF recurrences, 20 (76.9%), 4 (15.4%), and 2 (7.7%) events were classified as AF, AT, or both. Of 28 arrhythmia events in the 19 RF patients with AT/ AF recurrences, 19 (67.9%), 7 (25%), and 2 (7.1%) events were classified as AF, AT, or both. The incidence of AT after PVI was not statistically significantly different between the 2 groups (P=0.55).
All patients who had been in sinus rhythm throughout days 90 and 365 were off membrane-active AADs.
For the intention-to-treat population, the end point was reached by 69% (CI, 58.0%-80.0%) and 67.6% (CI, 56.2%-79.0%) in the LB and RF groups, respectively (P=0.43).
Adverse Events
During follow-up, complications occurred in 6 (8.8%) and 3 (4.5%) patients in the LB and RF groups, respectively (P=0.49; Table 3 ).
In the LB group, 3 (4.4%) patients developed cardioembolic stroke. Two events (2.9%) were temporally linked to the procedure with 1 patient complaining of double vision immediately after the procedure, and magnetic resonance imaging revealed a cerebellar lesion. Procedure duration (130 minutes) and intraprocedural anticoagulation (mean activated clotting time, 315 seconds) were unremarkable. The other patient had a minor embolic stroke while being treated with rivaroxaban (perioral sensory deficit) at day 8 after the procedure. Both patients completely recovered without neurological deficits. During follow-up, 1 patient developed hemiparesis 10 months post-ablation after having paused apixaban, despite a CHA 2 DS 2 -VASc score of 5.
Moreover, in the LB group, phrenic nerve palsy (n=1; 1.5%) and false aneurysm (n=1; 1.5%) were observed. The patient with phrenic nerve palsy remained asymptomatic, and diaphragmatic function had recovered at 6-month follow-up visit. The false aneurysm was managed conservatively.
In the RF group, 2 patients (3%) developed a false aneurysm with 1 patient needing surgical repair. No deaths, pericardial tamponade, or atrioesophageal fistula occurred.
During follow-up, 1 patient (1.5% for both groups) with preexisting coronary artery disease in each group experienced a myocardial infarction.
Center Experience
To assess the influence of operator experience on the procedural and clinical outcomes, data from 2 highrecruiting centers (n=106 patients) were compared with data from 4 low-recruiting centers (n=19 patients; Figure 3 ).
Procedure times in high-recruiting centers were shorter than in low-recruiting centers for both groups (127±30 versus 180±47 minutes for LB; P=0.006 and 119±49 versus 169±36 minutes for RF; P=0.0004). No differences between treatment groups were noted at the individual centers (P=0.35 for LB versus RF in high-recruiting centers and P=0.51 for LB versus RF in low-recruiting centers).
The occurrence of the efficacy end point was similar between groups in the high-recruiting centers: 17 of 54 patients (Kaplan-Meier estimate, 68.8%; CI, 56.5%-81.1%) in the LB group versus 15 of 52 patients (70.7%; CI, 58.2%-83.2%) in the RF group (P=0.834) were free of AT/AF. Oppositely, in low-recruiting centers, a considerable numeric, although not statistically significant, difference between treatment arms was observed: 2 of 9 patients (77.8%; CI, 50.6%-100%) in the LB versus 4 of 10 patients (58.3%; CI, 26.8%-89.9%) in the RF group were free of AT/AF (P=0.629).
Repeat Procedures
Eight and 9 patients underwent repeat ablation using electroanatomical mapping for symptomatic AT/AF recurrence in the LB and RF groups, respectively. The intervention was performed 199±91 days after the index ablation. In the LB group, 3, 4, and 1 patients presented in sinus rhythm, AF and AT. In the RF group, 3, 4, and 2 patients presented in sinus rhythm, AF and AT. In 14 of 36 (39%) PVs in the LB group and in 8 of 18 (44%) PV pairs in the RF group, LA-to-PV reconduction was detected (P=0.77). In addition to PV reisolation, RA isthmus ablation was performed in 3 and 7 patients, LA linear ablation in 1 and 5 patients, and complex fractionated atrial electrogram ablation in 0 and 1 patient in the LB and RF group, respectively. No PV stenosis was detected during PV angiographies.
DISCUSSION
Recently, noninferiority of balloon catheters in comparison with wide-area circumferential PVI in patients with paroxysmal AF has been demonstrated in large-scale randomized trials. [11] [12] [13] The optimal ablation strategy for patients with persistent AF has been meticulously investigated, but it seemed that ablation beyond PVI did not confer to improved outcomes. 2, 3 Although in these studies, wide-area circumferential PVI using irrigated RF energy was performed, the data on potentially simpler ablation devices, such as balloon catheters, were lacking. This is the first prospectively randomized trial assessing the performance of a balloon catheter system in comparison with wide-area circumferential PVI in patients with persistent AF. The major finding was that both ablation strategies performed similarly effective with a 1-year AF-free success rate of ≈70% following a single procedure.
The data are well in line with previously published retrospective reports comparing the LB to RF ablation in this particular patient population and on cryoballoon ablation for persistent AF. 8, 9, 14 Of note, the European clinical outcome data were slightly better than the results of the US IDE trial (United States Investigational Device Exemption) in paroxysmal patients with AF.
11
This may be explained by (1) differences in postablation AF screening, which was more intense in the IDE study; (2) by the fact that even the use of β-blockers was defined as a treatment failure in the IDE study; and (3) because of longer LB experience in Europe being commercially available since 2009.
Present data suggest that patients with persistent AF may also be ablated using a balloon catheter achieving electric PVI as an accepted end point. 1 This is of utmost importance for smaller ablation centers that may now offer service to this particular patient population. However, patients with long-standing persistent AF may require ablation beyond PVI as suggested in previous studies. 15 Of note, balloon catheter ablation is confined to PVI. In the event of AT occurring during PVI, either additional (and costly) mapping equipment would be required or AT needs to be electrically converted. The latter approach, however, is associated with poorer outcome. 16 Remarkably, protocol adherence discouraging ablation beyond PVI (complex fractionated atrial electrogram, AT, or typical RA flutter) was high for the index ablation (128/134; 95.5%). In the repeat ablation procedures, however, approximately one third of patients received LA ablation beyond PVI plus RA flutter ablation in 10 of 17 patients, despite the fact that the ideal ablation strategy for AF recurrences in patients with durably isolated or passively activated PVs after an index ablation is still unknown.
Skin-to-skin procedure times were similar for both point-by-point ablation techniques with a trend toward longer ablation and fluoroscopy times for the LB. In search of quicker ablation devices, the second-generation cryoballoon achieving single-shot PVI in the vast majority of PVs may further improve procedural characteristics, but randomized data for patients with persistent AF is lacking. 17 Of note, in multicenter randomized trials, procedure times for the cryoballoon and RF also including a 30-minute waiting time after PVI were similar to the present data (RF, 140.9±54.9 minutes; cryoballoon, 124.4±39.0 minutes). 12 Center experience (eg, low-recruiting centers) did not change the 1-year outcome after LB PVI in this study, whereas a considerable, although not statistically significant, difference was observed for the RF approach (71% versus 58%). The comparison has to be interpreted with caution because of small patient numbers in the low-recruiting centers group. However, similar observations were reported for cryoballoon ablation in patients with paroxysmal AF, indicating that the results of balloon catheter-guided PVI are less operator dependent. 18 Unlike in previous reports, no difference was found with regards to procedure and fluoroscopy times between groups. As expected, more experienced operators were able to complete the procedures more quickly with both technologies. 19 Although the incidence of adverse events was similar in both groups, the safety profile differs between RF and LB. As expected phrenic nerve palsy occurred in a single patient the LB group only. Using balloon catheters, the expected incidence of phrenic nerve palsy lies in the range of 1% to 3.5%. 11, 12, [19] [20] [21] [22] Luckily, the vast majority of the reported palsies are reversible.
Remarkably, 3 patients experienced stroke in the LB group. However, only 2 events were temporally linked to the ablation procedure, and 1 stroke occurred after cessation of anticoagulation therapy 10 months postablation, despite a CHA 2 DS 2 -VASc score of 5. Because of the small sample size of this study, it might be premature to attribute a higher risk for thromboembolic events to the LB technology. Previous studies suggested a similar incidence of silent cerebral emboli compared with cryoballoon and RF ablation, 23 as well as larger registry studies have not reported an unusually elevated stroke risk after LB-guided PVI.
21,22,24

Limitations
The present results may not apply to patients with longstanding persistent AF, in whom ablation strategies that modify the substrate in addition to PVI have been associated with a favorable outcome. 25 The present patient population, however, had an AF history of 24 to 35 months, including electric cardioversions in ≈90% of patients. Remarkably, more than half of the enrolled patients had not been treated with membrane-active AADs before ablation (eg, first-line catheter ablation) in contrast to current and previous European Society of Cardiology guidelines in the management of patients with AF. 26, 27 This progressive approach may have been triggered by recent reports on the superiority of catheter ablation over AAD therapy in patients with persistent AF. 28 The overall success rate as determined by the efficacy end point may have been lower, if more extensive follow-up strategies (7-day Holter, transtelephonic ECG monitors) had been used. However, first, this applies uniformly to both groups, and thus does not confound the results, and second, the rate of clinically relevant arrhythmia recurrences leading to medical intervention were detected in any case.
No formal sample size calculation was performed. Therefore, data have to be interpreted with caution and larger follower study would be desirable for confirmation.
Conclusions
This is the first randomized multicenter study assessing the outcome of PVI using 2 different ablation devices in patients with persistent AF. An LB-guided strategy was associated with similar efficacy as wide-area circumferential PVI using irrigated RF.
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